Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunovaccine, a developer of clinical stage vaccine based on its patented DepoVax vaccine delivery technology and product candidates, has reported Phase I clinical trial positive results of its therapeutic cancer vaccine DPX-0907.
Subscribe to our email newsletter
The study is an open-label, dose-escalating trial which is designed to evaluate the safety and immunogenicity of DPX-0907 in patients with advanced stage breast, ovarian or prostate cancer.
The Phase I trial has met the primary objective of safety with overall results demonstrating that DPX-0907 is generally well tolerated by all patients and is considered safe at both dose levels.
The secondary objective was to assess whether administration of DPX-0907 could generate an immune response specific to the seven cancer antigens.
The data confirms the activity of DepoVax in humans and its potential to enhance immune responses to peptide vaccines.
The Phase I results also provide data to advance the clinical development of DepoVax-based vaccines.
Immunovaccine CSO and COO Marc Mansour said the T cells specific to the vaccine targets displayed multiple activation markers following vaccination, these poly-functional T cells are believed to be more effective in targeting cancer cells.